Third Quarter of the Fiscal Year Ending March 31, 2026
Sales composition ratio
Pharmaceutical Wholesale Business
In the pharmaceutical wholesale business, although there were negative impacts from factors such as the drug price revision and a decrease in sales in limited segments in localized areas due to competitive bidding, sales increased as efforts to focus on the sale of products eligible for the price maintenance premium, mainly anticancer drugs, and seasonal products such as influenza vaccines outweighed the decrease in revenue. On the profit side, however, profit decreased due to the impact of the aforementioned sales decline from competitive bidding and an increase in selling, general and administrative expenses. As a result of the above, net sales were 436,971 million yen (100.6% of the same period of the previous year), and segment profit (operating profit) was 3,816 million yen (75.2% of the same period of the previous year).
Pharmacy Business
In the pharmacy business, although the number of prescriptions decreased, revenue increased due to efforts to increase income from dispensing technical fees and pharmaceutical management fees. On the profit side, profit increased due to efforts to calculate dispensing fees related to family pharmacy functions and to manage costs. As a result of the above, net sales were 14,975 million yen (102.0% of the same period of the previous year), and segment profit (operating profit) was 187 million yen (109.1% of the same period of the previous year).
Veterinary Drug Wholesale Business
In the Veterinary Drug Wholesale Business, revenue increased, partly due to the consolidation of Arrow Medical Co., Ltd., which offset the negative impact of a changeover in products as some products began to be sold directly by the manufacturer. On the profit side, however, profit decreased as the effect of the increase in revenue was not enough to absorb the increase in costs resulting from the consolidation. As a result of the above, net sales were 9,488 million yen (108.2% of the same period of the previous year), and segment profit (operating profit) was 221 million yen (91.1% of the same period of the previous year).
Pharmaceutical Business (business of supporting introduction of unapproved drugs)
The Pharmaceutical Business (business of supporting introduction of unapproved drugs) is a new business launched in the current fiscal year, and no sales were posted in the consolidated nine-month period, while expenses necessary for business activities including research and development expenses came to 895 million yen, and segment loss amounted to the same amount of 895 million yen.
Nursing Care-related Rental and Other Business
In the Nursing Care-related Rental and Other Business, revenue increased due to factors including the consolidation of Kyowa Transportation Co., Ltd. in April 2025. On the profit side, the segment loss increased, as increases in selling, general and administrative expenses due to price rises, including personnel and fuel costs, could not be absorbed. As a result, net sales were 3,118 million yen (101.5% of that of the same period of the previous year), and segment loss (operating loss) was 146 million yen (segment loss for the same period of the previous year was 108 million yen).